Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a publicly traded company in the Life Sciences sector. Wiseek monitors SCNI SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

• Scinai Reports Q1 Net Income of $3.6M from Non-Cash Gain; Operating Loss Widens to $2.5M Amid Cash Crunch (2026-06-10)
• Scinai Immunotherapeutics Registers Resale of 16.3 Million ADSs, Creating Massive Dilution Overhang (2026-05-19)
• Scinai Immunotherapeutics seeks massive share authorization increase and executive pay hikes amid delisting threat (2026-05-12)
• Scinai Immunotherapeutics Files for Resale of 16.3M ADSs, Signaling Massive Potential Dilution (2026-05-08)
• Scinai Immunotherapeutics Finalizes Acquisition of CDMO Arm for Nominal Consideration, Reports Pro Forma Financials (2026-05-08)

Insider Transactions

SCNI files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.